The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...

A CDK4/6 inhibitor (CDK4/6i) combined with endocrine therapy has been the standard of care (SOC) as first-line treatment for hormone receptor–positive/HER2-negative ...

Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of most ...

The faculty open the episode by discussing how most patients with hormone receptor-positive, HER2-negative metastatic breast cancer begin treatment with a CDK4/6 inhibitor plus an aromatase inhibitor ...

Kisqali combined with an aromatase inhibitor improved iDFS in hormone receptor-positive, HER2-negative early breast cancer, with a 30% risk reduction in DDFS and distant recurrence-free survival. The ...

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast ...

BUFFALO, NY – August 13, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase ...

Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or in ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Learn Look Locate (LLL), a global leader in breast cancer education and patient support, is proud to announce the launch of a groundbreaking new educational webpage on aromatase inhibitors in ...

The SONIA study shows that early use of inhibitors that target both CDK4 and CDK6 (hereafter, CDK4/6) in metastatic breast cancer prolongs time on treatment but does not improve patient outcomes.